Nader Halim

- Directed all planning and execution to successfully raise $40 million in Series A financing, leveraging experience in drug development to effectively present business model and secure investors including Deerfield Management, IP Group (Longview Innovations), Penn Medicine, WARF Ventures, and BioAdvance. -Built company infrastructure to include a global outsourced research network designed to reduce capital expenditure and maximize efficiencies. -Managed all phases in the development of a cell therapy combination product, INN-001, aiming to reconstruct the lost nigrostriatal pathway in patients with Parkinson’s disease. -Coordinates logistics and operation of all research, manufacturing, and development processes.

- Partnered with executive leadership to define and implement R&D strategy while leading project and alliance management functions. - Streamlined goal tracking and progress monitoring of pipeline assets through collaboration with drug development team and the creation and integration of reporting systems.

- Innovated and executed company strategy for a data science start-up designed to empower physicians and accelerate research for patients through expansive clinical databases. - Spearheaded the construction and management of the clinical trial business, with the aim of effectively optimizing and reducing clinical development timelines. - Established external partnerships, interfaced with physicians, and designed fundraising initiatives. - Streamlined patient identification, increased enrollment, and minimized costs for clinical trials by collaborating with data scientists to integrate machine learning and algorithm development capabilities within the database. - Strategized the translation of information to physicians while ensuring compliance with HIPAA regulations. - Leveraged partnerships with physician groups to improve clinical trials and partnered with medical associations to compile and leverage databases within the platform.

- Spearheaded the discovery and evaluation of cutting-edge science in academia and start-up companies across multiple therapeutic areas and modalities. - Initiated due diligence efforts, presented outcomes and proposals to executive committees, and facilitated negotiations and final approvals in collaboration with business development and legal teams. - Cultivated relationships with academic partners throughout the East Coast and developed regional networks within the scientific community. - Drove awareness and reputation of ES&I by representing the company at speaking events and conferences.

- Defined company strategies related to key policy issues, including coding and coverage, biologics and specialty products, expanded access, and channel distribution. - Liaised with external academic partners and trade associations while collaborating with company stakeholders. - Ensured effective conveyance of company position on federal policy by coordinating with Federal Affairs team to prepare lobbyists. - Identified potential business impacts of federal policies, leveraging information to integrate organizational changes and lobby for policy changes.

Thesis Title: Regulation of Brain Glucose Metabolic Patterns by Protein Phosphorylation and Drug Therapy